For example, subjects with the GSTM1 deletion and high SHS exposure had a 26.3% reduction in TP (95% CI, −38.7% to −11.6%) (Figure 1), and obese subjects with high SHS exposure had a 24.1% reduction in TP (95% CI, −41.5% to −1.5%) compared with GSTM1 carriers and no or low SHS or absence of obesity, respectively (Figure 1). This evidence concerns the gene GSTM1 and obesity due to melanocortin 4 receptor deficiency.